Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase

Yakugaku Zasshi

Volumn 122, Issue 8, 2002, Pages 527-535

  Watabe, Tadashi ^a,b   Ogura, Kenichiro ^a   Nishiyama, Takahito ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

5 FU prodrug; Dihydropyrimidine dehydrogenase; Lethal drug interaction; MALDI TOF MS; Sorivudine

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; PYRIMIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SORIVUDINE; 5 (2 BROMOVINYL)URACIL; 5 BROMOURACIL; 5-(2-BROMOVINYL)URACIL; ANTIVIRUS AGENT; DRUG DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXIDOREDUCTASE; PRODRUG; URACIL ARABINOSIDE;

CANCER CHEMOTHERAPY; DEATH; DRUG FATALITY; ENZYME DEGRADATION; FLORA; HERPES ZOSTER; HUMAN; ISOTOPE LABELING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLITE; MOLECULAR GENETICS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DEFICIENCY; RADIOACTIVITY; REVIEW; TISSUE LEVEL; TOXICOKINETICS; ANIMAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG INTERACTION; GENETICS; RAT;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BROMOURACIL; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; NADP; OXIDOREDUCTASES; PRODRUGS; RATS;

EID: 0036675152     PISSN: 00316903     EISSN: None     Source Type: Journal    
DOI: 10.1248/yakushi.122.527     Document Type: Review

References (21)

1. Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare, A report on investigation of side effects of sorivudine: Deaths caused by interactions between sorivudine and 5-FU prodrugs, 1994, pp. 1-27.
2. Watabe T., Okuda, H., Ogura, K., Yakugaku Zasshi, 117, 910-921 (1997).
3. Watabe T., Sogo Rinsho, 48, 1451-1455 (1999).
4. Watabe T., Nishiyama T., Ogura K., Xenobio. Metabol. Dispos., 15, 265-274 (2000).
5. Okuda H., Nishiyama T., Ogura K., Nagayama S., Ikeda K., Yamaguchi S., Nakamura Y., Kawaguchi Y., Watabe T., Drug Metab. Dispos., 25, 270-273 (1997).
6. Okuda H., Ogura K., Kato A., Takubo H., Watabe T., J. Pharmacol. Exp. Ther., 287, 791-799 (1998).
7. Ogiwara T., Miue H., Nakamaru M., Ohtsuka T., Kumahara Y., Jpn. Pharmacol. Ther., 18, 507-523 (1990).
8. Ogura K., Nishiyama T., Takubo H., Kato A., Okuda H., Arakawa K., Fukushima M., Nagayama S., Kawaguchi Y., Watabe T., Cancer Lett., 122, 107-113 (1998).
9. Nishiyama T., Ogura K., Okuda H., Suda K., Kato A., Watabe T., Mol. Pharmacol., 54, 899 (2000)
10. Yokota H., Fernandez-Salguero P., Furuya H., Lin K., McBride O. W., Podschun B., Schnackerz K. D., Gonzalez F. J., J. Biol. Chem., 269, 23192-23196 (1994).
11. Albin N., Johnson M. R., Diasio R. B., DNA Seq., 6, 243-250 (1996).
12. Kimura M., Sakata S. F., Matoba Y., Matsuda K., Kontani Y., Kaneko M., Tamaki N., J. Nutr. Sci. Vitaminol., 44, 537-546 (1998).
13. Wilson R., Ainscough R., Anderson K., Baynes C., Berks M., Bonfield J., Burton J., Connell M., Copsey T., Cooper J., Coulson A., Craxton M., Dear S., Du Z., Durbin R., Favello A., Fraser A., Fulton L., Gardner A., Green P., Hawkins T., Hillier L., Jier M., Johnston L., Jones M., Kershaw J., Kirsten J., Laisster N., Latreille P., Lightning J., Lloyd C., Mortimore B., O'Callaghan M., Parsons J., Percy C., Rifken L., Roopra A., Saunders D., Shownkeen R., Sims M., Smaldon N., Smith A., Smith M., Sonnhammer E., Staden R., Sulston J., Thierry-Mieg J., Thomas K., Vaudin M., Vaufhan K., Waterston R., Watson A., Weinstock L., Wilkinson-Sproat J., Wohldman P., Nature, 368, 32-38 (1994).
14. Van Gelder R. N., Bae H., Palazzolo M. J., Krasnow M. A., Curr. Biol., 5, 1424-1436 (1995).
15. Diasio R. B., Harris B. E., Clin. Pharmacokinet., 16, 215-237 (1989).
16. Lu Z., Zhang R., Diasio R. B., Clin. Pharmacol., 58, 512-522 (1995).
17. Lu Z., Zhang R., Diasio R. B., Cancer Res., 53, 5433-5438 (1993).
18. Chazal M., Etienne M. C., Renée N., Bourgeon A., Richelme H., Milano G., Clin. Cancer Res., 2, 507-510 (1996).
19. Etienne M. C., Lagrange J. L., Dassonville O., Fleming R., Thyss A., Renee N., Schneider M., Demard F., Milano G., J. Clin. Oncol., 12, 2248-2253 (1994).
20. Jiang W., Lu Z., He Y., Diasio R. B., Clin. Cancer Res., 3, 395-399 (1997).
21. Sohn D. R., Cho M. S., Chung P. J., Ther. Drug Monit., 21, 152-154 (1999).